https://doi.org/10.1016/j.apsb.2025.08.017
This new article publication from
Acta Pharmaceutica Sinica B, discusses how RDYH58 functional exosomes target myofibroblasts loaded with siFKBP10 for the inhibition of collagen biosynthesis and secretion of IPF.
Idiopathic pulmonary fibrosis (IPF) is a complex interstitial lung disease in which myofibroblasts are the primary effector cells. FK506-binding protein (FKBP10), a procollagen chaperone, is upregulated in IPF and primarily localizes to myofibroblasts. Exosomes have garnered significant attention as novel drug delivery vehicles, particularly when engineered. However, myofibroblasts remain underexplored in terms of engineered exosome-based therapies and associated drug targets. In this study, RDYH58, a peptide that targets myofibroblasts, was conjugated to the exosomal membrane protein Lamp2b to produce RDYH58-linked exosomes (RDYH58-exo).
In vitro and
in vivo experiments demonstrated that compared to unmodified exosomes (unm-exo), RDYH58-exo preferentially localized to myofibroblasts. A small interfering RNA targeting FKBP10 (siFKBP10) was loaded into exosomes using ultrasonic microfluidics method, and the antifibrotic effects of RDYH58-exo carrying siFKBP10 (RDYH58-siFKBP10) were assessed both
in vitro and
in vivo. The results demonstrated that RDYH58-siFKBP10 effectively silenced FKBP10 gene expression, significantly inhibiting fibroblast activation and extracellular matrix deposition, with superior antifibrotic efficacy compared to unmodified exosome vectors (unm-siFKBP10). RNA-seq analysis confirmed the pivotal regulatory role of FKBP10, providing critical evidence for the development of targeted therapeutic strategies. The RDYH58-siFKBP10 delivery system developed in this study demonstrates remarkable clinical translation potential.
Keywords: Idiopathic pulmonary fibrosis, Myofibroblasts, FK506-Binding protein, RDYH58, Exosomes, Drug delivery, Small interfering RNA, Ultrasonic microfluidics method
Graphical Abstract: available
https://ars.els-cdn.com/content/image/1-s2.0-S2211383525005696-ga1_lrg.jpg
This study utilized exosomes targeting myofibroblasts (RDYH58-exo) loaded with FKBP10-specific small interfering RNA (RDYH58-siFKBP10) to assess their anti-fibrotic effects both
in vitro and
in vivo.
# # # # # #
The Journal of the
Institute of Materia Medica, the Chinese Academy of Medical Sciences and the
Chinese Pharmaceutical Association.
For more information please visit
https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/
Editorial Board: https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b/editorial-board
APSB is available on
ScienceDirect (
https://www.sciencedirect.com/journal/acta-pharmaceutica-sinica-b).
Submissions to
APSB may be made using
Editorial Manager® (
https://www.editorialmanager.com/apsb/default.aspx).
CiteScore: 24.3
Impact Factor: 14.6 (Top 6 journal in the category of Pharmacology and pharmacy)
JIF without self-citation: 13.8
ISSN 2211-3835
# # # # #
Ranran Yuan, Zhen Mu, Houqian Zhang, Yu Tian, Quanlin Xin, Qingchao Tu, Yan Zhang, Yanqiu Li, Zhiwen Zhang, Yongchao Chu, Aiping Wang, Jingwei Tian, Hongbo Wang, Chong Qiu, Yanan Shi, RDYH58 functional exosomes targeting myofibroblasts loaded with siFKBP10 for inhibition of collagen biosynthesis and secretion of IPF, Acta Pharmaceutica Sinica B, Volume 15, Issue 12, 2025, Pages 6681-6697, ISSN 2211-3835,
https://doi.org/10.1016/j.apsb.2025.08.017